AI Article Synopsis
- HIV prevalence among trans women in Canada shows 7.5% are HIV positive, with significant gaps in HIV status data, as 38.1% had missing information.
- Factors associated with higher HIV rates include being Black, an immigrant or refugee, receiving social assistance, and a history of recreational drug use.
- The study emphasizes the need for better HIV testing and support tailored to the unique socioeconomic challenges faced by trans women in Canada.*
Article Abstract
Background: HIV prevalence data among transgender (trans) people are not routinely collected in national estimates, including Canada, contributing to gender-based inequities. We examined HIV prevalence and associated factors among trans women in clinical care in two large Canadian cities.
Methods: Retrospective chart data of trans women aged 16+ were collected from six family medicine and/or HIV clinics in Montreal and Toronto, Canada, 2018-2019. Multinomial logistic regression was used to analyze factors associated with documented HIV positive or missing HIV status relative to documented HIV negative status.
Results: Among 1,059 patients, 7.5% were HIV positive, 54.4% HIV negative, and 38.1% missing HIV data. Findings showed lower odds of being HIV positive for those <30 years or 30-50 years (vs. >50 years); higher odds were seen for those: of Black race/ethnicity (vs. white), landed immigrant or refugee (vs. Canadian citizen), receiving social assistance (vs. not), and whom ever having used recreational drugs.
Conclusions: Albeit high, the prevalence of HIV was lower than expected based on global estimates. Missing HIV status data suggest gaps in testing. Findings highlight socioeconomic and clinical realities among trans women in Canada and inform future HIV prevention and support.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/09564624231185818 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
State Medicaid Policies Governing Access to Medications for Opioid Use Disorder (MOUD) and MOUD Treatment Use in a Large Sample of People Who Inject Drugs in 20 U.S. States.
Subst Use Misuse
December 2024
Department of Health Policy and Management, Rollins School of Public Health at Emory University, Atlanta, GA, USA.
Background: People who inject drugs (PWID) are especially vulnerable to harms from opioid use disorder (OUD). Medications for OUD (MOUD) effectively reduce overdose and infectious disease transmission risks.
Objective: We investigate whether state Medicaid coverage for methadone and buprenorphine is related to past-year MOUD use among PWID using cross-sectional, multilevel analyses with individual-level data on PWID from the Centers for Disease Control and Prevention's 2018 National HIV Behavioral Surveillance.
Myelopathy as the first manifestation of AIDS.
AIDS Res Ther
December 2024
Department of Neurology, Xi'an International Medical Center Hospital, xitai road, gaoxin District, Xi'an city, Shaanxi Province, China.
Background: Human immunodeficiency virus (HIV) is a retrovirus mainly infecting immune cells. Central nervous system diseases in HIV-infected patients can be caused by HIV or opportunistic infections. Neurological diseases associated with HIV have diverse manifestations and may occur in early or late stages.
View Article and Find Full Text PDFOutcomes of percutaneous endoscopic gastrostomy (PEG) in HIV patients.
BMC Gastroenterol
December 2024
Division of Gastroenterology, Department of Medicine, BronxCare Health System, Clinical Affiliate of Mt Sinai Health Systems and Academic Affiliate of Icahn School of Medicine, 10C, 1650 Selwyn Avenue, Bronx, NY, 10457, USA.
Background: Percutaneous Endoscopic Gastrostomy (PEG) tube insertion, a routine procedure for long-term enteral nutrition, serves as a crucial intervention for patients who are incapable of tolerating oral intake or meeting adequate nutritional requirements. PEG tube placement carries complications like bleeding and infection. Impact of PEG tubes on the 30-day and long-term mortality in HIV patients is unknown.
View Article and Find Full Text PDFTelemedicine for HIV care: a cross-sectional survey of people living with HIV receiving care at two federally qualified health centers in Los Angeles during a mature phase of the COVID-19 pandemic.
BMC Infect Dis
December 2024
Division of Infectious Diseases, David Geffen School of Medicine at UCLA, Los Angeles, CA, US.
Background: The COVID-19 pandemic resulted in the rapid implementation of telemedicine for HIV care at federally qualified health centers (FQHCs) in the United States. We sought to understand use of telemedicine (telephone and video) at two FQHCs in Los Angeles, and the client attitudes towards and experiences with telemedicine as part of future HIV care.
Methods: We conducted surveys with 271 people living with HIV (PLHIV), with questions covering sociodemographic factors, telemedicine attitudes and experiences, technological literacy, and access to technological resources and privacy.
Cigarette smoking is associated with reduced neuroinflammation and better cognitive control in people living with HIV.
Neuropsychopharmacology
January 2025
Department of Psychiatry, University of California San Diego, San Diego, CA, USA.
People living with HIV (HIV+) are roughly twice as likely to smoke cigarettes (Smok+) as the general population. With the advent of effective antiretroviral therapies, it is increasingly important to understand the effects of chronic HIV infection and cigarette smoking on brain function and cognition since HIV+ individuals have heightened neuroinflammation and cognitive deficits even with such therapies. Based on prior studies demonstrating that smoking reduces a marker for neuroinflammation in HIV- individuals, we hypothesized that HIV+/Smok+ individuals would have less neuroinflammation and better cognitive control than HIV+/Smok- individuals.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!